Everand Logo

Welcome to Everand!

  • STAT

    Listen: Drug industry infighting, the human side of genetic medicine, and a big year for the microbiome

    Can biopharma police itself? Who decides whether something's a disease or a difference? And will fecal matter ever become a drug? Find out on the latest episode of "The Readout…
    by Damian Garde and Rebecca Robbins and Adam Feuerstein Feb 20, 2020 1 minute

    Can biopharma police itself? Who decides whether something’s a disease or a difference? And will fecal matter ever become a drug?

    We discuss all that and more on the latest

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
    Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

    Related